BridgeMD
New treatment option for Inappropriate Prescribing
Official title Deprescribing Inappropriate Proton Pump Inhibitors
ClinicalTrials.gov ID: NCT06129474
What this study is testing
- What it's testing
- The DROPIT Trial is an interventional, open-labelled, cluster-randomized controlled trial conducted in the Swiss primary care setting. It aims to evaluate an intervention to guide the deprescribing of inappropriate proton-pump inhibitors (PPIs).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient of a participating GP.
- Age: minimum 18 years old.
- Daily PPI intake for minimum 8 weeks.
- PPI in one of the following doses:
- minimum 40mg/day pantoprazole;
You likely can't join if
- Limited life expectancy according to GP judgement (patients with terminal disease and a life expectancy of less than 12 months.
- Unable to provide informed consent.
- PPI in an appropriate dose (see Appendix Table A1) and with an established indication for long-term PPI, such as:
- History of bleeding ulcer.
- Peptic ulcer due to cause other than NSAID or H. Pylori.
- Barrett's oesophagus.
See the full eligibility criteria
- Patient of a participating GP.
- Age: minimum 18 years old.
- Daily PPI intake for minimum 8 weeks.
- PPI in one of the following doses:
- minimum 40mg/day pantoprazole;
- minimum 40mg/day omeprazole;
- more than 30mg/day lansoprazole;
- more than 30mg/day dexlansoprazole;
- more than 20mg/day esomeprazole;
- more than 20mg/day rabeprazole.
- Sufficient knowledge of German language to understand the trial and follow-up according to GP assessment.
- Limited life expectancy according to GP judgement (patients with terminal disease and a life expectancy of less than 12 months.
- Unable to provide informed consent.
- PPI in an appropriate dose (see Appendix Table A1) and with an established indication for long-term PPI, such as:
- History of bleeding ulcer.
- Peptic ulcer due to cause other than NSAID or H. Pylori.
- Barrett's oesophagus.
- Severe erosive reflux disease (Los Angeles grade C/D).
- GERD with symptoms or complications (oesophageal ulcer, peptic stricture).
- Other indications (i.e., Zollinger-Ellison-Syndrome, PPI-sensitive eosinophilic esophagitis, chronic pancreatitis with steatorrhea refractory to enzyme replacement therapy, idiopathic pulmonary fibrosis.)
- Two or more of the following medications, or one of the following medications and one or more of the mentioned risk factors mentioned below. Medications (any dose):
- Daily use of non-steroidal anti-inflammatory drug (NSAID) for more than 7 days.
- Antiplatelet therapy.
- Additional antiplatelet therapy (e.g., ticagrelor or similar).
- Anticoagulant(s).
- Systemic steroid(s) for more than 1 month. Risk factors:
- History of gastrointestinal ulcer.
- Age of 75 years and older.
- Selective serotonin reuptake inhibitor (SSRI) or serotonin and norepinephrine reuptake inhibitor (SNRI) use.
- Severe concomitant disease with increased risk of GI bleeding according to the GP's assessment (e.g., severe liver disease, neoplasia, nicotine or alcohol abuse).
The study team makes the final eligibility decision.
Where it's taking place
- Bern, Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bern, Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.